Topical Finasteride Through Telehealth: The FDA Caution

Topical finasteride sold through telehealth is a compounded product: there is no FDA-approved topical finasteride in the US. On 22 April 2025 the FDA alerted prescribers, compounders and consumers to adverse-event reports linked to compounded topical finasteride, and said some patients had been told by prescribers that a topical carried no risk.

This guide sets out what the FDA said, which of the services we compare sell a topical containing finasteride, and the questions to ask before one ships. It is not a verdict on whether the products work, which is a question for the evidence and your prescriber.

What the FDA said

The FDA's alert makes five points, all on its own page. First, there are two FDA-approved oral finasteride products and no approved topical formulation, so compounded topicals have no FDA-approved labelling. Second, it had received 32 reports to its adverse-event system between 2019 and 2024 about compounded topical finasteride.

Third, because finasteride is expected to be absorbed through the skin into the bloodstream, the reports describe effects consistent with the oral tablets, including erectile dysfunction, anxiety, suicidal ideation, brain fog, depression, fatigue, insomnia, decreased libido and testicular pain; most reports said the effects continued after the product was stopped. Fourth, some consumers were unaware of the risks, and some said prescribers had told them there was no risk because the product was topical. Fifth, topicals add risks of their own: skin reactions, and a greater chance of exposing other people, especially women, through transfer.

What the alert does not say

The alert does not ban compounded topical finasteride, and it does not say every topical user will have side effects. It does not give a rate, because adverse-event reports show that problems were reported, not how often they happen. What it does say is that the risks are real, that topicals have no approved labelling, and that patients must be told about them before starting.

Why transfer matters

Finasteride can cause abnormalities of the external genitals of a male fetus, which is why its label says it must not be used by women who are or may become pregnant, and that they should not handle crushed or broken tablets. The approved tablets are coated, which prevents contact during normal handling.

A compounded topical has no coating. It sits on your scalp, your pillow and your hands, and the FDA's alert says there may be a greater risk of exposing others with a topical than with the approved tablets. If anyone in your home is or may become pregnant, tell the prescriber before a topical is even discussed.

Which services sell topical finasteride

All five services we compare sell at least one product that puts finasteride on the scalp. The table names them as each service does, from pages read on 22 September 2026, with the compounding label each service printed.

Four of the five label the product as compounded in plain words. Keeps labels its Minoxidil+ Spray as compounded, but its finasteride gel and drop appear without the same label on its product grid; ask before ordering.

What the approved tablets' label already says

The oral tablets are not risk-free either, and the topical reports matter because they look like the tablets' known effects. The Propecia label lists, among effects reported in general use, sexual side effects that continued after stopping, depression, and suicidal ideation and behaviour, as well as breast tenderness and enlargement.

The label also says finasteride is for men only, and that it can lower PSA, the blood test used to screen for prostate cancer, so anyone screened should tell the doctor. None of that is a reason to panic, and none of it is advice: it is what the prescriber should talk through with you, whichever form you are offered.

Questions to ask before a topical ships

A good prescriber will welcome these questions; a service that brushes them aside is telling you something.

1. Is this product FDA-approved, or compounded? If compounded, which pharmacy makes it?
2. What does the FDA's 2025 alert on compounded topical finasteride mean for me?
3. Why a topical rather than the approved tablet, in my case?
4. What side effects should make me stop and contact you, and how quickly will you reply?
5. What should I do about transfer to other people in my home?

Write the answers down, or keep the message thread, so you have them if something changes months later. If a clinician tells you a topical has no risk, the FDA's alert says patients reported being told exactly that, and it was not true for them.

What a careful service does

A careful service treats a topical finasteride request the way the FDA's alert asks prescribers to: as a medicine with real risks, not a gentler cosmetic. You can see the difference on the page before you ever start a consultation.

It labels every compounded product in plain words beside the price, not only in a footnote. It names, or will tell you on request, the pharmacy that mixes the product. It offers the approved tablet as a real alternative and explains why it would choose one over the other for you. It raises transfer to other people without being asked. And it tells you how to reach the clinician if something changes, and how fast they reply.

None of the five services does all of that on its public pages, which is why no service scored full marks for compounding labels. The questions above are the way to find out the rest.

How this affects our scores

Our comparison gives 15 points out of 100 for compounding labels, because this is the question where plain words protect people. Ro, Hims and Strut Health scored 14 each; Keeps scored 9 for the gaps on its product grid; Happy Head scored 8, partly for a footer that says topical finasteride carries a lower risk of side effects, set against this alert.

The rest of the scoring, and the price of the approved generic tablet at each service, is on our online hair-loss services compared page. For the cheapest way to fill an approved generic prescription, see what finasteride costs.

Where to report a side effect

If you have a side effect from any finasteride product, tell your prescriber first. The FDA also asks consumers and clinicians to report adverse events and quality problems with compounded drugs to MedWatch, its safety reporting programme, online or on a downloadable form sent by fax; the alert links to both.

Reports are how the FDA found this pattern in the first place, so a report is useful even if you are not sure the product caused the problem. For warning signs about the services themselves, read red flags in online prescribing.